SHORT REPORT

Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up

Benjamin Sorrungr Naovarat,1 Gloria Salazar,1 Mariko Ishimori,2 Francis M Williams,3 John D Reveille 1

ABSTRACT

Objective This study examined the safety and efficacy of biological agents, especially tumour necrosis factor (TNF)-α inhibitors, for HIV-positive rheumatology patients refractory to standard therapy.

Methods This study is a retrospective case series including patients derived from a community HIV clinic as well as from two academic centres. Initial visit data collected included: sociodemographic characteristics, CD4 counts, HIV viral load and medication use. Patients with persistent disease activity despite standard conservative therapy were begun on biological agents. The main outcomes were patient and physician global assessment of treatment response and medication side effects in patients with rheumatological disorders treated with biological medications over time.

Results Seventeen patients were seen from 2003 to 2021, including eight from our previous cohort published in 2008 and nine seen since then, five of whom taking TNF blockers for more than 10 years. Those (17.7%) had rheumatoid arthritis, five (29.4%) psoriatic arthritis, four (23.5%) axial spondyloarthritis and the rest (29.4%) peripheral spondyloarthritis. Antiretroviral therapy had been used in 15. All but one had at least a partial response to biological therapy. There were no major infectious episodes necessitating the discontinuation of medications with only one patient discontinuing treatment due to rising HIV viral load. Patients not on antiretroviral therapy reported no adverse side effects from biological therapy. Four patients were switched to ustekinumab, secukinumab, tocilizumab or upadacitinib from anti-TNF therapy without complications.

Conclusions These data suggest that biological therapy, especially anti-TNF agents are safe and well tolerated in HIV positive individuals even over several years.

INTRODUCTION

Tumour necrosis factor (TNF)-α plays an essential role in the host defence against intracellular pathogens; however, TNF-α has also been implicated in the pathogenesis of HIV-1 infection by promoting HIV replication in T-cell lines and in lymphocytes.1-3 Anti-TNF therapy and other biological treatments are now commonly used in patients suffering from rheumatological conditions; however, their usage in HIV-1 patients has been met with concern given that anti-TNF therapy increases susceptibility to infections especially with Mycobacterium tuberculosis, atypical mycobacteria and as well as other microorganisms.4 Little is known regarding the safety and efficacy of newer biologics developed over the last decade, such as interleukin-6 (IL-6), interleukin 12/23 (IL-12/23), interleukin-17 (IL-17) and Janus kinase inhibitors. However, there have been such studies reported in patients with HIV infection and psoriasis.5

We previously reported our experience with anti-TNF agent usage in eight HIV positive patients with rheumatic diseases in 2008.6 Few case reports published since that time have reported long-term follow-up data. Given that patients with rheumatic conditions in the setting of HIV-1 infection may not respond to conventional therapy, we sought to analyse the efficacy of treatment for various rheumatic conditions treated with anti-TNF therapy as well as other biological agents.
Additionally, we assessed the safety of biologics through documentation of adverse side effects through the course of every patient’s care on anti-TNF therapy or other biological treatment. Thus, the primary outcomes of our study are the safety and efficacy of these medications for patients with concomitant HIV infection and rheumatic disease followed over the course of their care.

METHODS

This cohort includes 15 patients seen at Thomas Street Clinic, the HIV outpatient clinic operated by the Harris County Hospital District since 1989 (of whom two patients subsequently transferred their care to the University of Texas McGovern Medical School University Practice (UTH)) as well as two other patients seen over the same period in whom the senior author (JDR) was either directly (at UTH) or indirectly (with the primary rheumatologist at the Cedars-Sinai Medical Centre (MI)) involved in their care, both included in our original series.6 All patients had rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA). All but one of the patients were cared for by the senior author (JDR) who confirmed the diagnoses by clinical impression as well as by approved criteria and that the inclusion and exclusion criteria were met.7–10 The remaining patient, seen at Cedars-Sinai Medical Centre and reported previously,6 had the diagnosis confirmed by the site rheumatologist (MI). In this study, not only do we present long-term follow-up data on the original eight patients, but include nine additional patients that we have cared for since then in whom biological treatment was used in the setting of HIV infection, including four patients that switched from anti-TNF therapy to other biological agents such as IL-6, IL-12/23, IL-17 and JAK inhibitors with no significant side effects. At baseline and subsequent visits, the following were collected: patient demographics, associated rheumatic disease, the presence and type of combined antiretroviral therapy (cART) used as well as other medication use, CD4 counts and viral loads. In addition to chart review, the investigators used the US Social Security Death databases to find patients that were lost to follow-up. All patients were screened for latent tuberculosis at their first clinic visit with those on biological therapy rechecked annually. Additionally, patients were also screened for hepatitis A, B and C at their first clinic visit with liver function tests monitored at least annually. If the patient had hepatitis C, they were treated with anti-HCV medications. We defined efficacy with the remission of symptoms by patient and physician global assessments. Moreover, we defined safety in this study as the lack of adverse side effects such as infection or allergic reaction, specifically, by serious infection as requiring hospitalisation or the need for drug discontinuation as a direct result, allergic response of other serious side effect. Disease activity scores, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) levels were not consistently collected at every visit. Moreover, ESR and CRP are more difficult to interpret in the setting of HIV infection. Follow-up visits were scheduled every 4–6 months, often depending on other medications that were being taken or as their disease required. Inclusion criteria were that the patient had concomitant HIV-1 infection and a rheumatic disease where anti-TNF therapy was commonly used, specifically RA, SpA or PsA, where the patient had active disease as judged by the clinician refractory to non-steroidal anti-inflammatory drugs and/or disease-modifying antirheumatic drugs (DMARDs). Exclusion criteria included patients that were on anti-TNF therapy not long enough to evaluate efficacy. With the recommendations for immunosuppressive agents in HIV-1 positive patients, anti-TNF therapy was not started in any individual with a CD4 count of less than 200 cells/µL or a HIV-1 viral load of greater than 60 000 copies/µL.11 Laboratory studies were performed through the commercial laboratories usually used by these clinics. The decision to change biological, therapy was made based on either lack of response or drug side effects, just as would be done in the non-HIV setting. For this study, descriptive statistical analyses were performed.

RESULTS

Between February 1994 and February 2022, 1797 unduplicated patients were seen at the Thomas Street Clinic, of whom 20 had RA, 22 PsA and 60 SpA, including 3 with ankylosing spondylitis (AS), 2 with non-radiographic axial SpA and 55 with either peripheral or undifferentiated SpA (non-AS patients seen before the axial and peripheral SpA criteria were published8 9 were called undifferentiated SpA). Of these, 15 were treated with anti-TNF or other biological/anti-JAK agents (2 RA-10%, 4 PsA-18.2%, 4 Axial SpA/AS-80% and 5 peripheral/undifferentiated SpA-9.1%). Including the additional nine patients described above, 17 patients with rheumatic diseases refractory to DMARDs were treated with anti-TNF or other biological agents seen between 2003 and 2021. The current status of the original eight patients published in 2008 are shown in table 1, and the data on the additional nine patients included since then in table 2. Three patients were lost to follow-up, two in 2015, and one in 2018 with duration of long-term follow-up of 12, 14 and 9 years, respectively. The average age at first visit was 42.9±7.8 years and 64.7% were male. In addition, our cohort was predominantly black (70.6%) with three white (17.7%) and two Latino patients (11.8%) respectively. Baseline CD4 count was 765.5±570.9 cells/µL with the lowest CD4 count on biological therapy was 641.8±344.5 cells/µL and the most recent average CD4 count 1013.7±922.4 cells/µL. No patient in our cohort dropped below 200 cells/µL with cART being used in 82.4%. There were no infectious episodes requiring hospitalisation that necessitated the discontinuation of medications while on biological therapy. From our cohort of 17 patients, 4 (23.5%) switched from anti-TNF to other biological or JAK inhibitor treatment. Patients who were
### Table 1  HIV-1 positive patients seen from 2003 to 2007 on anti-TNF therapy

| Patient number | 1    | 2    | 3    | 4    | 5    | 6    | 7    | 8    |
|----------------|------|------|------|------|------|------|------|------|
| Age at first visit | 48   | 34   | 31   | 49   | 44   | 39   | 47   | 52   |
| Gender | Male | Male | Male | Female | Male | Female | Male | Male |
| Ethnicity | White | White | Black | Black | Black | Black | Black | White |
| Rheumatic disease | Seropositive RA plus psoriasis | ankylosing spondylitis (AS) | Peripheral SpA | Peripheral SpA | Peripheral SpA | PsA | PsA | PsA |
| Biologic/JAK inhibitor usage | Currently taking | Taken previously | Not taking | Switched to tocilizumab | Not taking | Not taking | Switched to secukinumab then ustekinumab | Lost to follow-up |
| Taking cART | Yes | Yes | No | Yes | No | No | Yes | Yes |
| Baseline CD4 (cells/μL) | 631 | 634 | 745 | 373 | 1300 | 970 | 365 | 268 |
| Baseline viral load (copies/mL) | Undetectable | 256 | Undetectable | Undetectable | Undetectable | 27829 | 15667 | Undetectable |
| Duration of anti-TNF treatment | 2003–2011, 2016–present | 2004 | 2003–2005 | 2003–2017 | 2004–2005 | 2004–2007 | 2006–present | 2003–2007 |
| Still followed | Current patient | Followed elsewhere after 2006, alive 2021 | Last visit 2015 | Current patient | Current patient | Last visit 2018 | Current patient | Last seen 2015 |
| Lowest CD4 on anti-TNF treatment (cells/μL) | 357 | 634 | 923 | 580 | 1082 | 750 | 382 | 240 |
| Highest viral load on anti-TNF treatment (copies/mL) | 103 | 845 | Undetectable | 120000 | Undetectable | 428503 | <400 | Undetectable |
| Most recent CD4 count (cells/μL) | 468 | 690 | 535 | 1026 | 993 | 321 | 1121 | 417 |
| Most recent HIV viral load (copies/mL) | Undetectable | Undetectable | 193 | Undetectable | Undetectable | 77 | Undetectable | Undetectable |
| Anti-TNF agent used | Etanercept, Adalimumab | Etanercept | Etanercept | Etanercept, adalimumab, infliximab | Etanercept | Etanercept, infliximab, adalimumab | Etanercept, adalimumab, infliximab | Etanercept, infliximab |

Continued
not on cART reported no adverse side effects to biological therapy and no opportunistic infections. Moreover, for patients that were taking daily corticosteroids, there were no complications with biological treatment. In the overall cohort, three (17.7%) had RA, five (29.4%) PsA, three (17.7%) axial SpA and the rest (35.5%) peripheral SpA, including three previously classified as reactive arthritis. From our cohort, 12 patients had a good to excellent clinical response to biological therapy with near total symptomatic remission (by physician and patient assessment). Additionally, four patients had a partial or transient response with only one patient having no perceived benefit from anti-TNF therapy. Eleven patients had no adverse side effects of biological therapy. Patient 1 in our series experienced one herpetic lesion 1 week after beginning etanercept; however, there was a previous history of recurrent herpetic lesions and his symptoms resolved without any treatment or complications. In addition, patient 1 had a history of recurrent facial abscesses secondary to poor dentition both on and off biologic and he was subsequently taken off this treatment in 2021 in anticipation of dental implant surgery. Patient 3 was the only one in our cohort that developed anterior acute uveitis while on etanercept therapy. Patients 6 and 9 had transient increases in HIV-1 viral load requiring temporary discontinuation, but this did not recur with subsequent treatments. Patient 8 had a facial abscess while on infliximab that responded to antibiotic therapy that resolved without any further complications or recurrence. Furthermore, patient 7 had an allergy to secukinumab as was switched to ustekinumab. Three patients switched from anti-TNF therapy to interleukin inhibitors due to disease flares on treatment and had symptom remission thereon. Patient 13 switched from etanercept to upadacitinib due to persisting symptoms and has had an excellent clinical response to treatment.

**DISCUSSION**

This retrospective case series builds on and extends our previous report that suggests the use of biological agents is safe and effective in HIV-1 positive patients with rheumatic diseases, now even long term. Biological agents were begun only when patients failed initial standard antirheumatic therapy and treatment was not started unless CD4 count was >200 mm⁻³ and HIV viral load was <60,000 copies/mm⁻³. There were no infectious events that necessitated permanent discontinuation of therapy; however, given that there was no HIV-1 positive control group, it is impossible to speculate the significance of this. However, there has been research that has shown that HIV-infected patients on anti-TNF therapy have the same rate of serious infection as patients from registries.

Since our publication in 2008, there have been a few case reports that address anti-TNF treatment and other biological therapy with HIV-1 infection: one using etanercept, one using infliximab, and one using...
Table 2  HIV-1 positive patients seen from 2008 to 2021 on anti-TNF therapy

| Patient number | Age at first visit | Gender | Ethnicity | Rheumatic disease | Anti-TNF agent usage | Duration of anti-TNF treatment | Still followed | Baseline CD4 (cells/μL) | Baseline viral (copies/mL) | Lowest CD4 on anti-TNF treatment (cells/μL) | Highest viral load on anti-TNF treatment (copies/mL) | Most recent CD4 count (cells/μL) | Most recent HIV viral load | Anti-TNF agent used | Other biologic/anti-JAK agents used | Clinical response to therapy | Complications of biological treatment |
|----------------|-------------------|--------|-----------|-------------------|---------------------|-------------------------------|----------------|-------------------------|--------------------------|---------------------------------|---------------------------------|-------------------------|-------------------------|----------------|-----------------------------|----------------|-----------------------------|
| 9              | 35                | Male   | Black     | Enteropathic arthritis (Peripheral SpA) | Not taking          | 2006–2010                     | Current patient | 583                     | 1788                      | 403                             | 35200                           | 583                     | 164 000                 | Adalimumab       | None                        | Partial          | None                        |
| 10             | 30                | Male   | Hispanic  | PsA                | Currently taking    | 2010–present                 | Current patient | 185                     | 535                       | 303                             | 43 700                           | 771                     | 38                      | Etanercept, adalimumab    | None                        | Good            | None                        |
| 11             | 49                | Male   | Black     | Ankylosing spondylitis (AS) | Not taking          | 2013–2013                    | Current patient | 614                     | Undetectable              | 677                             | Undetectable                   | 1040                    | Undetectable            | Etanercept       | None                        | Good            | None                        |
| 12             | 36                | Male   | Black     | PsA                | Currently taking    | 2010–present                 | Current patient | 562                     | Undetectable              | 217                             | Undetectable                   | 365                     | Undetectable            | Etanercept       | None                        | Good            | None                        |
| 13             | 48                | Male   | Black     | Seronegative RA    | Switched to upadacitinib| 2013–2016, 2020–present     | Current patient | 599                     | 4500                      | 599                             | 834                             | 365                     | Undetectable            | Adalimumab       | None                        | Good            | None                        |
| 14             | 49                | Male   | Hispanic  | Non-radiographic axial SpA | Not taking          | 2014–2014                    | Current patient | 440                     | Undetectable              | 389                             | Undetectable                   | 3852                   | Undetectable            | Upadacitinib    | None                        | Excellent        | None                        |
| 15             | 36                | Male   | Black     | Peripheral SpA     | Currently taking     | 2019–present                 | Current patient | 1300                    | Undetectable              | 1144                            | Undetectable                   | 1757                    | Undetectable            | Adalimumab       | None                        | Excellent        | None                        |
| 16             | 53                | Female | Hispanic  | PsA                | Switched to secukinumab | 2020–present                 | Current patient | 827                     | Undetectable              | 815                             | Undetectable                   | 2689                    | Undetectable            | Adalimumab       | None                        | Good            | None                        |
| 17             | 49                | Female | Black     | PsA                | Currently taking     | 2020–present                 | Current patient | 2618                    | Undetectable              | 1416                            | Undetectable                   | 2402                    | Undetectable            | Adalimumab       | None                        | Good            | None                        |

cART, combined antiretroviral therapy; JAK, Janus kinase; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis; TNF, tumour necrosis factor.
secukinumab.13–15 Liang et al described one patient on etanercept for RA long-term which demonstrated safety and efficacy; while, Rafael et al described a patient that was successfully treated with infliximab for Crohn’s disease. Vilchez-Oya et al described one case of secukinumab for axial SpA and reviewed four additional cases of anti-IL-17 monoclonal antibody use that demonstrated safety and efficacy in this setting. Also, as previously noted, was a series of 23 patients with HIV infection with psoriasis, but without rheumatic disease, treated with etanercept, methotrexate or ustekinumab.3 However, our study adds to and further elaborates on these case studies by reporting on 17 patients followed between a period of 2–18 years with a variety of rheumatic conditions on anti-TNF and other biological therapy. Not only have our patients demonstrated long-term safety in the use of these therapeutic agents; but they have had long-term effectiveness and symptom remission while on therapy through clinician and patient assessment.

Strengths of this study include granular long-term follow-up data on a cohort of patients with concomitant HIV-1 infection and clinician-diagnosed rheumatic disease. A weakness includes the lack of quantitative measures that could have been used to document the efficacy of these therapies. However, any adverse side effect was documented in the medical record as well as any cause for hospitalisation. Thus, over long-term follow-up, anti-TNF and IL-blocking agents appear to be safe and efficacious in patients with HIV-1 with concomitant rheumatic conditions. For patients that have failed standard rheumatic therapy, these agents provide a means for achieving symptomatic remission without major adverse opportunistic infections or any detrimental effects on CD4 counts or viral load. These data underscore that if a patient’s HIV-1 infection is well controlled and the patient not significantly immunocompromised, biological agents can be considered as a viable option for treating a variety of rheumatic diseases.

Acknowledgements The authors would like to acknowledge the contribution of numerous rheumatology fellows over the years who participated in the care of these patients, and most of all, of the patients we have cared for at Thomas Street Clinic over these past 32 years.

Collaborators not applicable.

Contributors BSN did the data abstraction from the charts and wrote this manuscript, and presented the data at the 2021 American College of Rheumatology Convergence meeting. GS and FMW assisted in the care of these patients at Thomas Street Clinic over the years, and MI provided the clinical data from the one Cedars-Sinai patient in this and the 2008 manuscript. JDR supervised the care of these patients since the inception of the clinic in 1990. All these authors assisted in the drafting and final approval of this article.

Funding There was no pharma or other support for this study, other than funding from the Department of Health and Human Services-Ryan White Title I (DHHS) Grant for Rheumatology Services 6H12AA000390-09 (3/1/98-present).

Competing interests None declared.

Patient and public involvement statement The risks and benefits of biological therapy in the setting of HIV infection were discussed with all of the patients whose deidentified clinical data were presented in this and our previous manuscript, as well as that sharing these experiences would likely result in the better care of patients with HIV presenting with rheumatic diseases and all patients approved.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the University of Texas Medical School Committee for the Protection of Human Subjects (HSC-MS-09-0672).

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their work on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
John D Reveille http://orcid.org/0000-0001-5990-0913

REFERENCES
1 Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405–17.
2 Poli G, Facuci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5:165–73.
3 Vaidya SA, Korner C, Sirignano MN, et al. Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV type 1 infection. J Infect Dis 2014;210:1046–2.
4 Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013–22.
5 Montes-Torres A, Aparicio G, Rivera R, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. J Dermatolog Treat 2019;30:461–5.
6 Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008;67:710–2.
7 Aleataha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
8 Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of spondyloarthritis International Society classification criteria for axial spondyloarthritis (Part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
9 Rudwaleit M, van der Heijde D, Landewe R, et al. The assessment of spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.
10 Taylor W, Gladman D, Heilwell R, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
11 Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63 Suppl (2):i18–24.
12 Wangsricharoen S, Ligon C, Gedmintas L, et al. Rates of serious infections in HIV-infected patients receiving tumor necrosis factor inhibitor therapy for concomitant autoimmune diseases. Arthritis Care Res 2017;69:449–52. s.
13 Liang S-J, Zheng Q-Y, Yang Y-L, et al. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatol Int 2017;37:1207–12.
14 Rafael MA, Lourenço LC, Oliveira AM, et al. Successful treatment of severe perianal Crohn’s disease with infliximab in an HIV-positive patient. Clin J Gastroenterol 2019;12:583–7.
15 Vilchez-Oya F, Orpinell Palacio L, Castillo Viellet M, et al. The use of secukinumab in an HIV-positive patient with axial spondyloarthritis: a case-based review. Clin Rheumatol 2021;40:5111–4.